تداخلات ليفلونوميد

It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2) ] . (نشرة أداليموماب، تحذير مؤطر)

Immunosuppressants Everolimus Sirolimus Temsirolimus (IV) Not recommended during and 2 weeks after TOLSURA treatment. (نشرة إيتراكونازول، التداخلات الدوائية)

…IN TRANSPLANT PATIENTS; AND INCREASED MORTALITY IN FEMALE LIVER TRANSPLANT PATIENTS • Increased risk for developing serious infections and malignancies with ASTAGRAF XL ® or other immunosuppressants that may lead to hospitalization or death. [see Warnings and Precautions ( 5.1 , 5.2 )] • Increased mortality in female liver transplant patients with ASTAGRAF XL. (نشرة تاكروليموس، تحذير مؤطر)

Patients being treated with teriflunomide [see Drug Interactions (7) ] . (نشرة ليفلونوميد، موانع الاستعمال)

Immunosuppressant/neoplastic: everolimus Co-administration of everolimus and PREZISTA/ritonavir is not recommended. irinotecan Discontinue PREZISTA/ritonavir at least 1 week prior to starting irinotecan therapy. (نشرة دارونافير، التداخلات الدوائية)

In kidney, liver, and heart transplant patients Neoral may be administered with other immunosuppressive agents. (نشرة سيكلوسبورين، تحذير مؤطر)

Chicken pox and measles, for example, can have a more serious or even fatal course in children on immunosuppressant corticosteroids. (نشرة فلودروكورتيزون، التحذيرات)

Persons who are on immunosuppressant doses of corticosteroids should be warned to avoid exposure to chickenpox or measles. (نشرة فلونيسوليد، الاحتياطات)

About 13 percent of the cases of neutropenia have ended fatally, but almost all fatalities were in patients with serious illness, having collagen vascular disease, renal failure, heart failure or immunosuppressant therapy, or a combination of these complicating factors. (نشرة كابتوبريل، التحذيرات)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (نشرة كلادريبين، التداخلات الدوائية)

…methylergonovine • HMG-CoA reductase inhibitors: lovastatin, simvastatin (these drugs can be temporarily discontinued to allow PAXLOVID use [see Table 2 , Drug Interactions (7.3) ] ) • Immunosuppressants: voclosporin • Microsomal triglyceride transfer protein inhibitor: lomitapide • Migraine medications: eletriptan, ubrogepant • Mineralocorticoid receptor antagonists:… (نشرة نيرماتريلفير وريتونافير، موانع الاستعمال)

If used with concomitant methotrexate and/or other potential immunosuppressive agents, chronic monitoring should be monthly. (نشرة ليفلونوميد، التحذيرات والاحتياطات)

If used with concomitant methotrexate and/or other potential immunosuppressive agents, chronic monitoring should be monthly. (نشرة ليفلونوميد، التحذيرات والاحتياطات)

Immunosuppressants: cyclosporine, sirolimus, tacrolimus ↑ immunosuppressants Therapeutic concentration monitoring is recommended for these immunosuppressants when coadministered with REYATAZ. (نشرة أتازانافير، التداخلات الدوائية)

For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while… (نشرة ليفلونوميد، التداخلات الدوائية)

In patients taking ARAVA, exposure of drugs metabolized by CYP1A2 (e.g., alosetron, duloxetine, theophylline, tizanidine) may be reduced. (نشرة ليفلونوميد، التداخلات الدوائية)

If used with concomitant methotrexate and/or other potential immunosuppressive agents, chronic monitoring should be monthly. (نشرة ليفلونوميد، التحذيرات والاحتياطات)

Effect on Oral Contraceptives Teriflunomide may increase the systemic exposures of ethinylestradiol and levonorgestrel. (نشرة ليفلونوميد، التداخلات الدوائية)

Effect on Oral Contraceptives Teriflunomide may increase the systemic exposures of ethinylestradiol and levonorgestrel. (نشرة ليفلونوميد، التداخلات الدوائية)

Effect on Oral Contraceptives Teriflunomide may increase the systemic exposures of ethinylestradiol and levonorgestrel. (نشرة ليفلونوميد، التداخلات الدوائية)

Effect on Oral Contraceptives Teriflunomide may increase the systemic exposures of ethinylestradiol and levonorgestrel. (نشرة ليفلونوميد، التداخلات الدوائية)

Effect on Oral Contraceptives Teriflunomide may increase the systemic exposures of ethinylestradiol and levonorgestrel. (نشرة ليفلونوميد، التداخلات الدوائية)

Effect on Oral Contraceptives Teriflunomide may increase the systemic exposures of ethinylestradiol and levonorgestrel. (نشرة ليفلونوميد، التداخلات الدوائية)

Immuno-suppressants: e.g., cyclosporine (CsA) sirolimus tacrolimus ↑ immuno-suppressants ↑ elvitegravir (with CsA) ↑ cobicistat (with CsA) Therapeutic monitoring of the immunosuppressive agents is recommended upon coadministration with GENVOYA. (نشرة إلفيتيغرافير وكوبيسيستات وإمتريسيتابين وتينوفوفير، التداخلات الدوائية)

In patients taking ARAVA, exposure of drugs metabolized by CYP1A2 (e.g., alosetron, duloxetine, theophylline, tizanidine) may be reduced. (نشرة ليفلونوميد، التداخلات الدوائية)

In patients taking ARAVA, exposure of drugs metabolized by CYP1A2 (e.g., alosetron, duloxetine, theophylline, tizanidine) may be reduced. (نشرة ليفلونوميد، التداخلات الدوائية)

If used with concomitant methotrexate and/or other potential immunosuppressive agents, chronic monitoring should be monthly. (نشرة ليفلونوميد، التحذيرات والاحتياطات)

In patients taking ARAVA, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased. (نشرة ليفلونوميد، التداخلات الدوائية)

In patients taking ARAVA, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased. (نشرة ليفلونوميد، التداخلات الدوائية)

Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (نشرة أملوديبين، التداخلات الدوائية)

For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while… (نشرة ليفلونوميد، التداخلات الدوائية)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (نشرة أملوديبين وأولميسارتان، التداخلات الدوائية)

Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when coadministered. (نشرة أملوديبين وفالسارتان، التداخلات الدوائية)

In patients taking ARAVA, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased. (نشرة ليفلونوميد، التداخلات الدوائية)

In patients taking ARAVA, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased. (نشرة ليفلونوميد، التداخلات الدوائية)

In patients taking ARAVA, exposure of drugs metabolized by CYP1A2 (e.g., alosetron, duloxetine, theophylline, tizanidine) may be reduced. (نشرة ليفلونوميد، التداخلات الدوائية)

If used with concomitant methotrexate and/or other potential immunosuppressive agents, chronic monitoring should be monthly. (نشرة ليفلونوميد، التحذيرات والاحتياطات)

If used with concomitant methotrexate and/or other potential immunosuppressive agents, chronic monitoring should be monthly. (نشرة ليفلونوميد، التحذيرات والاحتياطات)

In patients taking ARAVA, exposure of drugs metabolized by CYP1A2 (e.g., alosetron, duloxetine, theophylline, tizanidine) may be reduced. (نشرة ليفلونوميد، التداخلات الدوائية)

If used with concomitant methotrexate and/or other potential immunosuppressive agents, chronic monitoring should be monthly. (نشرة ليفلونوميد، التحذيرات والاحتياطات)

If used with concomitant methotrexate and/or other potential immunosuppressive agents, chronic monitoring should be monthly. (نشرة ليفلونوميد، التحذيرات والاحتياطات)

In patients taking ARAVA, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased. (نشرة ليفلونوميد، التداخلات الدوائية)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (نشرة أولميسارتان وأملوديبين وهيدروكلوروثيازيد، التداخلات الدوائية)

If used with concomitant methotrexate and/or other potential immunosuppressive agents, chronic monitoring should be monthly. (نشرة ليفلونوميد، التحذيرات والاحتياطات)

Immunosuppressants : cyclosporine sirolimus tacrolimus ↓ immunosuppressant Etravirine and systemic immunosuppressants should be co-administered with caution because plasma concentrations of cyclosporine, sirolimus, or tacrolimus may be affected. (نشرة إيترافيرين، التداخلات الدوائية)

Effect on Oral Contraceptives Teriflunomide may increase the systemic exposures of ethinylestradiol and levonorgestrel. (نشرة ليفلونوميد، التداخلات الدوائية)

Effect on Oral Contraceptives Teriflunomide may increase the systemic exposures of ethinylestradiol and levonorgestrel. (نشرة ليفلونوميد، التداخلات الدوائية)

…(e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while patients are taking ARAVA [see… (نشرة ليفلونوميد، التداخلات الدوائية)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus and others metabolized by CYP3A ↓ immunosuppressant Dose adjustments of the immunosuppressant may be required. (نشرة إيفافيرينز، التداخلات الدوائية)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus, and others metabolized by CYP3A ↓ immunosuppressant Dose adjustments of the immunosuppressant may be required. (نشرة إيفافيرينز ولاميفودين وتينوفوفير، التداخلات الدوائية)

If used with concomitant methotrexate and/or other potential immunosuppressive agents, chronic monitoring should be monthly. (نشرة ليفلونوميد، التحذيرات والاحتياطات)

If used with concomitant methotrexate and/or other potential immunosuppressive agents, chronic monitoring should be monthly. (نشرة ليفلونوميد، التحذيرات والاحتياطات)

In patients taking ARAVA, exposure of drugs metabolized by CYP2C8 (e.g., paclitaxel, pioglitazone, repaglinide, rosiglitazone) may be increased. (نشرة ليفلونوميد، التداخلات الدوائية)

…other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while patients… (نشرة ليفلونوميد، التداخلات الدوائية)

Effect on Oral Contraceptives Teriflunomide may increase the systemic exposures of ethinylestradiol and levonorgestrel. (نشرة ليفلونوميد، التداخلات الدوائية)

In patients taking ARAVA, exposure of drugs metabolized by CYP1A2 (e.g., alosetron, duloxetine, theophylline, tizanidine) may be reduced. (نشرة ليفلونوميد، التداخلات الدوائية)

In patients taking ARAVA, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased. (نشرة ليفلونوميد، التداخلات الدوائية)

In patients taking ARAVA, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased. (نشرة ليفلونوميد، التداخلات الدوائية)

Treatment has consisted of high doses of corticosteroids alone or, in some cases, concomitantly with an immunosuppressant. (نشرة بنسيلامين، التحذيرات)

In patients taking ARAVA, exposure of drugs metabolized by CYP1A2 (e.g., alosetron, duloxetine, theophylline, tizanidine) may be reduced. (نشرة ليفلونوميد، التداخلات الدوائية)

In patients taking ARAVA, exposure of drugs metabolized by CYP1A2 (e.g., alosetron, duloxetine, theophylline, tizanidine) may be reduced. (نشرة ليفلونوميد، التداخلات الدوائية)

In patients taking ARAVA, exposure of drugs metabolized by CYP1A2 (e.g., alosetron, duloxetine, theophylline, tizanidine) may be reduced. (نشرة ليفلونوميد، التداخلات الدوائية)

In patients taking ARAVA, exposure of drugs metabolized by CYP1A2 (e.g., alosetron, duloxetine, theophylline, tizanidine) may be reduced. (نشرة ليفلونوميد، التداخلات الدوائية)

If used with concomitant methotrexate and/or other potential immunosuppressive agents, chronic monitoring should be monthly. (نشرة ليفلونوميد، التحذيرات والاحتياطات)

In patients taking ARAVA, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased. (نشرة ليفلونوميد، التداخلات الدوائية)

If used with concomitant methotrexate and/or other potential immunosuppressive agents, chronic monitoring should be monthly. (نشرة ليفلونوميد، التحذيرات والاحتياطات)

Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (نشرة بينداموستين، التحذيرات والاحتياطات)

In patients taking ARAVA, exposure of drugs metabolized by CYP2C8 (e.g., paclitaxel, pioglitazone, repaglinide, rosiglitazone) may be increased. (نشرة ليفلونوميد، التداخلات الدوائية)

In patients taking ARAVA, exposure of drugs metabolized by CYP2C8 (e.g., paclitaxel, pioglitazone, repaglinide, rosiglitazone) may be increased. (نشرة ليفلونوميد، التداخلات الدوائية)

In patients taking ARAVA, exposure of drugs metabolized by CYP2C8 (e.g., paclitaxel, pioglitazone, repaglinide, rosiglitazone) may be increased. (نشرة ليفلونوميد، التداخلات الدوائية)

If used with concomitant methotrexate and/or other potential immunosuppressive agents, chronic monitoring should be monthly. (نشرة ليفلونوميد، التحذيرات والاحتياطات)

If used with concomitant methotrexate and/or other potential immunosuppressive agents, chronic monitoring should be monthly. (نشرة ليفلونوميد، التحذيرات والاحتياطات)

In patients taking ARAVA, exposure of drugs metabolized by CYP1A2 (e.g., alosetron, duloxetine, theophylline, tizanidine) may be reduced. (نشرة ليفلونوميد، التداخلات الدوائية)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (نشرة تيمسيروليموس، التحذيرات والاحتياطات)

Cyclosporine, tacrolimus: Monitor for toxicities of these immunosuppressive drugs ( 7.1 ) (نشرة تينيدازول، التداخلات الدوائية)

If used with concomitant methotrexate and/or other potential immunosuppressive agents, chronic monitoring should be monthly. (نشرة ليفلونوميد، التحذيرات والاحتياطات)

In patients taking ARAVA, exposure of drugs metabolized by CYP1A2 (e.g., alosetron, duloxetine, theophylline, tizanidine) may be reduced. (نشرة ليفلونوميد، التداخلات الدوائية)

Frequent PT/INR determinations are advisable until it has been definitely determined that the PT/INR has stabilized Immunosuppressants Clinical Impact: Immunosuppressants such as cyclosporine and tacrolimus can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route… (نشرة حمض الفينوفيبريك، التداخلات الدوائية)

Therapeutic drug monitoring is recommended with concomitant use Immunosuppressant /neoplastic: everolimus ↑ immunosuppressants Co-administration of everolimus and PREZCOBIX or PREZCOBIX PED is not recommended. irinotecan Discontinue PREZCOBIX or PREZCOBIX PED at least 1 week prior to starting irinotecan therapy. (نشرة دارونافير وكوبيسيستات، التداخلات الدوائية)

Effect on Oral Contraceptives Teriflunomide may increase the systemic exposures of ethinylestradiol and levonorgestrel. (نشرة ليفلونوميد، التداخلات الدوائية)

In patients taking ARAVA, exposure of drugs metabolized by CYP1A2 (e.g., alosetron, duloxetine, theophylline, tizanidine) may be reduced. (نشرة ليفلونوميد، التداخلات الدوائية)

Effect on Oral Contraceptives Teriflunomide may increase the systemic exposures of ethinylestradiol and levonorgestrel. (نشرة ليفلونوميد، التداخلات الدوائية)

In patients taking ARAVA, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased. (نشرة ليفلونوميد، التداخلات الدوائية)

Other risk factors for the development of ONJ include immunosuppressive therapy, treatment with angiogenesis inhibitors, systemic corticosteroids, diabetes, and gingival infections. (نشرة دينوسوماب، التحذيرات والاحتياطات)

Rosuvastatin: The dose of rosuvastatin should not exceed 10 mg once daily in patients taking ARAVA. (نشرة ليفلونوميد، التداخلات الدوائية)

In patients taking ARAVA, exposure of drugs metabolized by CYP2C8 (e.g., paclitaxel, pioglitazone, repaglinide, rosiglitazone) may be increased. (نشرة ليفلونوميد، التداخلات الدوائية)

If used with concomitant methotrexate and/or other potential immunosuppressive agents, chronic monitoring should be monthly. (نشرة ليفلونوميد، التحذيرات والاحتياطات)

If used with concomitant methotrexate and/or other potential immunosuppressive agents, chronic monitoring should be monthly. (نشرة ليفلونوميد، التحذيرات والاحتياطات)

Immunosuppressants: cyclosporine, tacrolimus, sirolimus (rapamycin) ↑ immunosuppressants Therapeutic concentration monitoring is recommended for immunosuppressant agents when co-administered with ritonavir. (نشرة ريتونافير، التداخلات الدوائية)

…Digoxin Corticosteroids Prednisone Fibrates Clofibrate Oral Hypoglycemics Sulfonylureas (e.g., glyburide, glipizide) Hormonal Contraceptives/Progestins Ethinyl estradiol, levonorgestrel Immunosuppressants Cyclosporine, tacrolimus Methylxanthines Theophylline Narcotic analgesics Methadone Phosphodiesterase-5 (PDE-5) Inhibitors Sildenafil Thyroid preparations Levothyroxine… (نشرة ريفابنتين، التداخلات الدوائية)

Concomitant use of ARAVA and rifampin, a potent inducer of CYP and transporters, increased the plasma concentration of teriflunomide by 40%. (نشرة ليفلونوميد، التداخلات الدوائية)

In patients taking ARAVA, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased. (نشرة ليفلونوميد، التداخلات الدوائية)

HBV reactivation has also been reported in patients receiving certain immunosuppressant or chemotherapeutic agents; the risk of HBV reactivation associated with treatment with HCV direct-acting antivirals may be increased in these patients. (نشرة سوفوسبوفير وفيلباتاسفير، التحذيرات والاحتياطات)

In patients taking ARAVA, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased. (نشرة ليفلونوميد، التداخلات الدوائية)

If used with concomitant methotrexate and/or other potential immunosuppressive agents, chronic monitoring should be monthly. (نشرة ليفلونوميد، التحذيرات والاحتياطات)

In patients taking ARAVA, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased. (نشرة ليفلونوميد، التداخلات الدوائية)

If used with concomitant methotrexate and/or other potential immunosuppressive agents, chronic monitoring should be monthly. (نشرة ليفلونوميد، التحذيرات والاحتياطات)

If used with concomitant methotrexate and/or other potential immunosuppressive agents, chronic monitoring should be monthly. (نشرة ليفلونوميد، التحذيرات والاحتياطات)

…(e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while patients are taking ARAVA [see… (نشرة ليفلونوميد، التداخلات الدوائية)

In patients taking ARAVA, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased. (نشرة ليفلونوميد، التداخلات الدوائية)

If used with concomitant methotrexate and/or other potential immunosuppressive agents, chronic monitoring should be monthly. (نشرة ليفلونوميد، التحذيرات والاحتياطات)

In patients taking ARAVA, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased. (نشرة ليفلونوميد، التداخلات الدوائية)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus ↑ Immunosuppressants Therapeutic concentration monitoring is recommended for immunosuppressant agents. (نشرة فوسامبرينافير، التداخلات الدوائية)

Effect on Oral Contraceptives Teriflunomide may increase the systemic exposures of ethinylestradiol and levonorgestrel. (نشرة ليفلونوميد، التداخلات الدوائية)

In patients taking ARAVA, exposure of drugs metabolized by CYP1A2 (e.g., alosetron, duloxetine, theophylline, tizanidine) may be reduced. (نشرة ليفلونوميد، التداخلات الدوائية)

If used with concomitant methotrexate and/or other potential immunosuppressive agents, chronic monitoring should be monthly. (نشرة ليفلونوميد، التحذيرات والاحتياطات)

Immunosuppressants Clinical Impact: Immunosuppressants such as cyclosporine and tacrolimus can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of fibrate drugs including fenofibrate, there is a risk that an interaction will lead to deterioration of renal… (نشرة فينوفيبرات، التداخلات الدوائية)

In patients taking ARAVA, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased. (نشرة ليفلونوميد، التداخلات الدوائية)

Immunosuppressants everolimus, rapamycin (also known as sirolimus), temsirolimus budesonide, ciclesonide, cyclosporine, dexamethasone, fluticasone, methylprednisolone, tacrolimus Rapamycin (sirolimus): Ketoconazole tablets 200 mg daily for 10 days increased the C max and AUC of a single 5 mg dose of sirolimus by 4.3 fold and 10.9 fold, respectively in 23 healthy… (نشرة كيتوكونازول، التداخلات الدوائية)

In patients taking ARAVA, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased. (نشرة ليفلونوميد، التداخلات الدوائية)

Immunosuppressants: e.g. cyclosporine, tacrolimus, sirolimus ↑ immunosuppressants Therapeutic concentration monitoring is recommended for immunosuppressant agents when co-administered with KALETRA. (نشرة لوبينافير وريتونافير، التداخلات الدوائية)

HBV reactivation has also been reported in patients receiving certain immunosuppressants or chemotherapeutic agents; the risk of HBV reactivation associated with treatment with HCV direct-acting antivirals may be increased in these patients. (نشرة ليديباسفير وسوفوسبوفير، التحذيرات والاحتياطات)

Teriflunomide may increase exposure of ethinylestradiol and levonorgestrel. (نشرة ليفلونوميد، التداخلات الدوائية)

Teriflunomide may increase exposure of ethinylestradiol and levonorgestrel. (نشرة ليفلونوميد، التداخلات الدوائية)

For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while… (نشرة ليفلونوميد، التداخلات الدوائية)

If ARAVA and methotrexate are given concomitantly, follow the American College of Rheumatology (ACR) guidelines for monitoring methotrexate liver toxicity with ALT, AST, and serum albumin testing. (نشرة ليفلونوميد، التحذيرات والاحتياطات)

Effect on Oral Contraceptives Teriflunomide may increase the systemic exposures of ethinylestradiol and levonorgestrel. (نشرة ليفلونوميد، التداخلات الدوائية)

Effect on Oral Contraceptives Teriflunomide may increase the systemic exposures of ethinylestradiol and levonorgestrel. (نشرة ليفلونوميد، التداخلات الدوائية)

If used with concomitant methotrexate and/or other potential immunosuppressive agents, chronic monitoring should be monthly. (نشرة ليفلونوميد، التحذيرات والاحتياطات)

Effect on Oral Contraceptives Teriflunomide may increase the systemic exposures of ethinylestradiol and levonorgestrel. (نشرة ليفلونوميد، التداخلات الدوائية)

If used with concomitant methotrexate and/or other potential immunosuppressive agents, chronic monitoring should be monthly. (نشرة ليفلونوميد، التحذيرات والاحتياطات)

If used with concomitant methotrexate and/or other potential immunosuppressive agents, chronic monitoring should be monthly. (نشرة ليفلونوميد، التحذيرات والاحتياطات)

For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while… (نشرة ليفلونوميد، التداخلات الدوائية)

In patients taking ARAVA, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased. (نشرة ليفلونوميد، التداخلات الدوائية)

Effect on Oral Contraceptives Teriflunomide may increase the systemic exposures of ethinylestradiol and levonorgestrel. (نشرة ليفلونوميد، التداخلات الدوائية)

Effect on Oral Contraceptives Teriflunomide may increase the systemic exposures of ethinylestradiol and levonorgestrel. (نشرة ليفلونوميد، التداخلات الدوائية)

Effect on Oral Contraceptives Teriflunomide may increase the systemic exposures of ethinylestradiol and levonorgestrel. (نشرة ليفلونوميد، التداخلات الدوائية)

Effect on Oral Contraceptives Teriflunomide may increase the systemic exposures of ethinylestradiol and levonorgestrel. (نشرة ليفلونوميد، التداخلات الدوائية)

Effect on Oral Contraceptives Teriflunomide may increase the systemic exposures of ethinylestradiol and levonorgestrel. (نشرة ليفلونوميد، التداخلات الدوائية)

Immunosuppressive Agents There have been reports of increased blood concentrations of cyclosporine and tacrolimus into toxic ranges when patients received these drugs concomitantly with nefazodone. (نشرة نيفازودون، التداخلات الدوائية)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus Plasma concentrations may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Warfarin: Monitor INR as teriflunomide may decrease INR. (نشرة ليفلونوميد، التداخلات الدوائية)

Thirty-four patients were treated with corticosteroids and one patient was treated with a non-steroidal immunosuppressant. (نشرة أكسيتينيب، التحذيرات والاحتياطات)

In some cases, vasculitis resolved/improved with drug discontinuation; however, more severe cases required treatment with additional measures including corticosteroids, immunosuppressant therapy, and plasmapheresis. (نشرة بروبيل ثيوراسيل، التحذيرات)

CYP3A Substrates Immunosuppressants that are CYP3A4 Substrates Mechanism and Clinical Effect(s) Posaconazole is a strong CYP3A4 inhibitor. (نشرة بوساكونازول، التداخلات الدوائية)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (نشرة بيتافاستاتين، التحذيرات والاحتياطات)

Effect on CYP2C8 Substrates Teriflunomide is an inhibitor of CYP2C8 in vivo . (نشرة ليفلونوميد، التداخلات الدوائية)

Effect on CYP2C8 Substrates Teriflunomide is an inhibitor of CYP2C8 in vivo . (نشرة ليفلونوميد، التداخلات الدوائية)

Effect on CYP2C8 Substrates Teriflunomide is an inhibitor of CYP2C8 in vivo . (نشرة ليفلونوميد، التداخلات الدوائية)

Effect on CYP2C8 Substrates Teriflunomide is an inhibitor of CYP2C8 in vivo . (نشرة ليفلونوميد، التداخلات الدوائية)

Effect on CYP2C8 Substrates Teriflunomide is an inhibitor of CYP2C8 in vivo . (نشرة ليفلونوميد، التداخلات الدوائية)

IMNM is characterized by proximal muscle weakness and elevated serum CK, which persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody, muscle biopsy showing necrotizing myopathy, and improvement with immunosuppressive agents. (نشرة فلوفاستاتين، التحذيرات والاحتياطات)

Effect on CYP1A2 Substrates Teriflunomide, the active metabolite of ARAVA, may be a weak inducer of CYP1A2 in vivo . (نشرة ليفلونوميد، التداخلات الدوائية)

Effect on CYP2C8 Substrates Teriflunomide is an inhibitor of CYP2C8 in vivo . (نشرة ليفلونوميد، التداخلات الدوائية)

Elimination can be accelerated by the following procedures: Administer cholestyramine 8 grams orally 3 times daily for 11 days. (نشرة ليفلونوميد، التحذيرات والاحتياطات)

IMNM is characterized by: proximal muscle weakness and elevated serum creatine kinase, which persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (نشرة لوفاستاتين، التحذيرات)

In some cases, vasculitis resolved/improved with drug discontinuation; however, more severe cases required treatment with additional measures including corticosteroids, immunosuppressant therapy, and plasmapheresis. (نشرة ميثيمازول، التحذيرات)

Immunosuppressive Drugs Tacrolimus: Tacrolimus has been shown to be metabolized via the CYP3A system. (نشرة نيفيديبين، الاحتياطات)

Effect on CYP2C8 Substrates Teriflunomide is an inhibitor of CYP2C8 in vivo . (نشرة ليفلونوميد، التداخلات الدوائية)

…Repaglinide, Rosiglitazone: [See Warnings and Precautions ( 5.4 ) and Adverse Reactions ( 6.2 )] Insulin Insulin: [See Warnings and Precautions ( 5.4 ) and Adverse Reactions ( 6.2 )] Immunosuppressants: Cyclosporine Use With Caution Cyclosporine: There have been spontaneous or published reports of CYP3A based interactions of clarithromycin with cyclosporine. (نشرة كلاريثرومايسين، التداخلات الدوائية)